Trial headlines usually chase the biggest number. This one matters for the opposite reason.
First, tolerability. The most common side effects in REDEFINE 9 were gastrointestinal — nausea, vomiting, constipation, diarrhea — and mostly mild to moderate, consistent with what GLP-1 users already know. Notably, only 2.9% of patients on the 1.7 mg dose and 4.9% on the 1.0 mg dose stopped treatment because of adverse events — the latter no higher than placebo, where 4.9% also discontinued. Dose is one of the biggest drivers of GI side effects across this drug class, so a lower maintenance dose that preserves most of the benefit could keep more people on treatment long enough to see results.
Second, flexibility. If regulators eventually include lower maintenance doses in the label, providers would have more room to individualize: not every patient needs, or tolerates, the maximum dose. Many patients on today's GLP-1s already plateau at middle doses with their provider's guidance.
Third, supply and cost. Lower-dose pens use less active ingredient. Novo Nordisk has not announced CagriSema pricing, so any dollar figure would be speculation — but a drug that works at lower doses is generally easier to manufacture at scale, which matters in a class that has repeatedly run into shortages.
One important caveat: REDEFINE 9 was not designed to compare the two doses against each other, so the nearly identical results do not prove the doses are interchangeable. That decision will sit with the FDA label and, ultimately, with prescribers.